{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=13&state=Utah",
    "query": {
      "state": "Utah",
      "city": "Salt Lake City",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 545,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=14&state=Utah&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=12&state=Utah&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T23:19:30.675Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03419234",
      "title": "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma in the Soft Tissue",
        "Prostate Carcinoma Metastatic in the Bone",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Androgen deprivation therapy",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 223,
      "start_date": "2018-04-26",
      "completion_date": "2028-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 665,
      "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03419234"
    },
    {
      "nct_id": "NCT05625633",
      "title": "Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Warts"
      ],
      "interventions": [
        {
          "name": "Human Papillomavirus 9-valent Vaccine, Recombinant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Western Institute for Veterans Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2024-03-25",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05625633"
    },
    {
      "nct_id": "NCT03365882",
      "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "ERBB2 Gene Amplification",
        "Rectal Adenocarcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Stage III Colon Cancer AJCC v7",
        "Stage III Rectal Cancer AJCC v7",
        "Stage IIIA Colon Cancer AJCC v7",
        "Stage IIIA Rectal Cancer AJCC v7",
        "Stage IIIB Colon Cancer AJCC v7",
        "Stage IIIB Rectal Cancer AJCC v7",
        "Stage IIIC Colon Cancer AJCC v7",
        "Stage IIIC Rectal Cancer AJCC v7",
        "Stage IV Colon Cancer AJCC v7",
        "Stage IV Rectal Cancer AJCC v7",
        "Stage IVA Colon Cancer AJCC v7",
        "Stage IVA Rectal Cancer AJCC v7",
        "Stage IVB Colon Cancer AJCC v7",
        "Stage IVB Rectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HER-2 testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2017-11-27",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 786,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03365882"
    },
    {
      "nct_id": "NCT04197479",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Resmetirom",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1343,
      "start_date": "2019-12-16",
      "completion_date": "2023-01-06",
      "has_results": false,
      "last_update_posted_date": "2023-09-05",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 76,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197479"
    },
    {
      "nct_id": "NCT05238025",
      "title": "MVA-BN-RSV Vaccine Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MVA-BN-RSV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tris Buffered Saline (TBS)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 20419,
      "start_date": "2022-04-19",
      "completion_date": "2023-09-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 105,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238025"
    },
    {
      "nct_id": "NCT06824194",
      "title": "Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Immunization"
      ],
      "interventions": [
        {
          "name": "PCV21 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxelis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAQTA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 2360,
      "start_date": "2025-02-18",
      "completion_date": "2027-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 103,
      "location_summary": "Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Oneonta",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06824194"
    },
    {
      "nct_id": "NCT05220137",
      "title": "Using the Multiphase Optimization Strategy to Adapt Cognitive Processing Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Disorders, Post-Traumatic"
      ],
      "interventions": [
        {
          "name": "Modified A-B-C: Working with Events, Thoughts, and Feelings",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Challenging Questions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patterns of Problematic Thinking",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Challenging Beliefs",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2022-08-01",
      "completion_date": "2026-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 3,
      "location_summary": "Ann Arbor, Michigan • Cincinnati, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220137"
    },
    {
      "nct_id": "NCT04129619",
      "title": "A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Diarrhea"
      ],
      "interventions": [
        {
          "name": "ORP-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OrphoMed, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 321,
      "start_date": "2019-11-22",
      "completion_date": "2021-10-04",
      "has_results": false,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04129619"
    },
    {
      "nct_id": "NCT06557772",
      "title": "A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coeliac Disease",
        "Celiac Disease"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SIGE",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Gluten-free product (GFP)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 229,
      "start_date": "2024-08-29",
      "completion_date": "2029-04-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • Arcadia, California • Lancaster, California + 32 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06557772"
    },
    {
      "nct_id": "NCT00023777",
      "title": "S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "56 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "56 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2001-08",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-10-30T23:19:30.675Z",
      "location_count": 98,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023777"
    }
  ]
}